Some observers have questioned whether there is
too much complacency in the markets, and
too little interest in protecting
against downside risk in equities.
Kwiatkowski and his team suspect that the variation might be subject to something called balancing selection — just like the sickle cell variation — where genes are selected because of their ability to protect
against malaria, but are kept from becoming
too common because of their potential
downsides.